2025-05-28
Angela Vollstedt joins NextCell Pharma’s Board of Advisors to Strengthen Scientific and Manufacturing Strategy Ahead of Licensing Discussions
NextCell Pharma AB ("NextCell" or "the Company") is pleased to announce the appointment of Dr. Angela Vollstedt, PhD, MBA, to its Board of Advisors, reinforcing the company’s strategic shift toward pivotal development and licensing of its lead drug candidate, ProTrans, for the treatment of type 1 diabetes. Dr. Vollstedt currently serves as Global Director of Cell & Gene Therapies Portfolio Management at Novartis, where she leads cross-functional teams in the development, scaling, and commercialisation of advanced therapies.
Read moreRead more2025-05-26
NextCell Receives US Patent for MSC Prediction Algorithm
NextCell Pharma AB ("NextCell" or "the Company") is pleased to announce the issuance of a US patent titled “MSC Prediction Algorithm” by the United States Patent and Trademark Office (USPTO). The patent protects NextCell’s innovative methodology for predicting the efficacy of mesenchymal stromal cell (MSC) therapy in individual patients, as well as the approach for determining personalised treatment options based on that prediction.
Read moreRead more2025-05-23
NextCell Pharma receives declarations of intent, subscription undertakings and top guarantees regarding exercise of TO2
THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, CANADA, HONG KONG, BELARUS, RUSSIA OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLISHING OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW. SEE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.
NextCell Pharma AB ("NextCell" or the "Company") issued a total of 38,711,804 warrants of series TO2 (“Warrants”) within the framework of a rights issue of units during the second quarter of 2024. The exercise period for the Warrants runs until and including 30 May 2025. One (1) Warrant entitles the holder to subscribe for one (1) new share in the Company at a subscription price of SEK 1.00 per share. NextCell today announces that the Company has received declarations of intent from all of the Company’s senior executives and Board members who hold Warrants and subscription undertakings from a selection of existing Warrant holders regarding the exercise of held Warrants, totalling approximately SEK 6.9 million, corresponding to approximately 17.8 percent of the total number of outstanding Warrants. In addition, the Company has secured top guarantees from a selection of existing Warrant holders and shareholders as well as external investors corresponding to an additional approximately 30 percent of the total issue volume. The top guarantees, together with the received declarations of intent and subscription undertakings, ensure that the Company will receive minimum proceeds of approximately SEK 18.5 million, corresponding to approximately 47.8 percent of the total issue volume.
Read moreRead more2025-05-20
NextCell announces strategic collaboration with Fujifilm Irvine Scientific
NextCell Pharma AB’s ("NextCell" or "the Company") has entered into a strategic collaboration with Fujifilm Irvine Scientific Inc. to bring together their core competences in mesenchymal stromal cells (MSCs) and raw materials for the life science sector. The aim of the collaboration is to provide researchers and developers in the cell therapy field with an integrated offering – standardised MSC products, optimised culture media, and cryopreservation solutions.
Read moreRead more2025-05-19
Eric Strati Joins NextCell Pharma’s Board of Advisors to Support Commercial Strategy for ProTrans
NextCell Pharma AB ("NextCell") is pleased to announce the appointment of Eric Strati, PharmD, MBA, as a new member of its Board of Advisors, marking a strategic step as the company transitions from a development-focused organization into a pivotal phase aimed at out-licensing and commercializing its leading cell therapy product, ProTrans, for the treatment of type 1 diabetes.
Read moreRead more2025-05-16
The exercise period for NextCell Pharma’s warrants of series TO2 begins today
THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, CANADA, HONG KONG, BELARUS, RUSSIA OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLISHING OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW. SEE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.
NextCell Pharma AB (“NextCell” or the “Company”) issued a total of 38,711,804 warrants of series TO2 (“Warrants”) within the framework of a rights issue of units during the second quarter of 2025. The exercise period for the Warrants commences today, on May 16, 2025, and continues until May 30, 2025. One (1) Warrant entitles the holder to subscribe for one (1) new share in the Company. The subscription price per share subscribed for through the exercise of Warrants has been set at SEK 1.00. Upon full utilization of all Warrants, NextCell will receive approximately SEK 38.7 million before issuance costs. The proceeds from the exercise of Warrants are mainly intended to support the completion of the ProTrans-Young study and continued clinical development, business development, and regulatory preparations for future market approval.
Read moreRead more2025-05-15
Eight-Year-Old Hugo – Living with Type 1 Diabetes and Participating in the ProTrans Study
NextCell Pharma AB ("NextCell") is featured in the Future Healthcare – Focus on Diabetes supplement of the Swedish national newspaper Svenska Dagbladet, through an article highlighting eight-year-old Hugo Wahlbeck, who is currently enrolled in the ongoing paediatric study with ProTrans – the Company’s leading investigational therapy for the treatment of type 1 diabetes.
Read moreRead more2025-05-07
Study published in Nature Medicine shows promising results in Alzheimer’s disease – supports the development of ProTrans at NextCell
NextCell Pharma AB (“NextCell” or the “Company”) highlights a recently published clinical trial demonstrating promising results for mesenchymal stromal cells (MSCs) in the treatment of mild Alzheimer’s disease. The results strengthen the scientific foundation for NextCell’s drug candidate ProTrans, which is being developed for autoimmune and inflammatory diseases. NextCell is developing the next generation of MSC therapies with a focus on selection and indication-specific tailoring using its patented platform technology.
Read moreRead more